Paper Details

  1. Home
  2. Paper Details

Effects of colestipol-niacin therapy on human femoral atherosclerosis.

Author: AzenS P, BlankenhornD H, CrawfordD W, NessimS A, SanmarcoM E, SelzerR H, ShircoreA M, WickhamE C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study examined the effect of cholesterol-lowering treatment on the progression of atherosclerosis in the femoral arteries of men who had previously undergone heart bypass surgery. The study found that the treatment, a combination of colestipol, niacin, and diet, significantly slowed the progression of atherosclerosis in segments with moderate to severe disease and in the proximal segments of the arteries. While significant, the effect was less pronounced than previously observed in coronary arteries.
Paper Details　
Original Abstract of the Article :
The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery. Different diet compositions ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/01.cir.83.2.438

データ提供：米国国立医学図書館（NLM）

Colestipol-Niacin Therapy: A Promising Approach to Combat Femoral Atherosclerosis

This study investigates the effects of colestipol-niacin therapy, coupled with dietary modifications, on the progression of femoral atherosclerosis. The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-plus-diet-controlled angiographic trial involving men who had undergone coronary bypass surgery. The researchers evaluated the impact of colestipol-niacin therapy on the rate of change in computer-estimated atherosclerosis (CEA) over a two-year period.

Significant Therapy Effect: A Positive Step Towards Atherosclerosis Management

The study revealed a significant therapy effect of colestipol-niacin therapy on segments with moderate to severe atherosclerosis and in proximal segments. Furthermore, a significant therapy effect was observed when segmental CEA measures were combined into a per-patient score. These findings suggest that colestipol-niacin therapy, in conjunction with dietary adjustments, may have a positive impact on the progression of femoral atherosclerosis.

A Promising Approach: Balancing Benefits and Considerations

While the study demonstrates a promising effect of colestipol-niacin therapy on femoral atherosclerosis, it's essential to note that the therapy effect was less pronounced than that observed in previous studies involving coronary arteries and bypass grafts. However, the results provide valuable insights into the potential benefits of this therapy for managing atherosclerosis, particularly in individuals with a history of coronary bypass surgery. Further research is warranted to fully elucidate its long-term effects and optimal application in various patient populations.

Dr. Camel's Conclusion

Atherosclerosis, like a relentless desert wind, can slowly erode our health. This study suggests that colestipol-niacin therapy, combined with a healthy diet, could offer a potential oasis in the fight against this chronic condition. While further exploration is necessary, the findings offer promising hope for individuals seeking to manage atherosclerosis and improve their cardiovascular health.

Date :
  1. Date Completed 1991-03-12
  2. Date Revised 2019-06-23
Further Info :

Pubmed ID

1991366

DOI: Digital Object Identifier

10.1161/01.cir.83.2.438

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.